

## **ECAT survey results on ADAMTS13 testing**

R.W.L.M. Niessen

Clinical chemist, Medical Laboratory Eastern Netherlands (MEDLON), The Netherlands

The ECAT frequently evaluates its quality control panel and in collaboration with the participants investigates if additional test have to be included into the external quality assessment programme in the field of haemostasis and thrombosis. At the moment interlaboratory comparison of ADAMTS13 testing is hampered by the lack of international standardization of ADAMTS13. Therefore, ECAT started in 2014 with regular surveys for ADAMTS13. Data of the three performed surveys are presented. The ADAMTS13 activity/antigen and the ADAMTS13 inhibitor was performed by 84 and 61 participants, respectively. In these surveys 4 different samples were used, with ADAMTS13 activity levels of <10, 20, 40 and 90 U/dL. In the first two surveys the same samples were used, with ADAMTS13 activity levels of 20 and 40 U/dL. The interlaboratory CV of ADAMTS13 activity had a range of 11.8 – 38.5% (total group CV 22.2%) at the level of 20 U/dL and a range of 10.1 – 23.7% (total group CV 18.4%) at the level of 40 U/dL. At the level of <10 and 90 U/dL the interlaboratory CV had a range of 16.8 – 34.6 (total group CV 25.6%) and of 9.7 – 13.3% (total group CV 12.2%), respectively.

In conclusion, with the number of participants in the ADAMTS13 surveys a fairly good interlaboratory comparison can be made, which can contribute in time in achieving a decrease in the interlaboratory CV.